Iovance Biotherapeutics, Inc. Stock News

Iovance Biotherapeutics, Inc. (IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced initial data from pivotal Cohort 4 and updated long-term

The Ethereum network now has more bitcoin held in reserves than the Lightning Network, according to onchain statistics. At the time of publication, Wrapped Bitcoin (WBTC) has close to 4,000 BTC ($34.7

Peter Adamson, a pediatric oncologist, brings urgency to his new role as Sanofi's research leader in cancer and pediatric innovation.

May 25, 2020 (The Market Signal via Comtex) -- Sector Reports was created as a platform to help investors find the best free Stock Reports on stocks they...

It really depends on which side you’re on, to be honest.

Biotech stocks closed the week ended May 22 higher, with stray clinical readouts and COVID-19 drug- and vaccine-related news moving stocks in the sector. Surface Oncology Inc (...

A BRISK walk or cycle ride every day boosts women's chances of surviving the deadliest breast cancers by almost 70 percent.

A new study has also revealed COVID-19 can block human genes, making it easier for the virus to multiply.

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 21) ADC Therapeutics SA (NYSE:...

CAIRO: Egyptian police have arrested four thieves who had been using masks of football star Mo Salah’s face to disguise their identity.  On Tuesday, a police patrol noticed four people wearing Mo S

Intensity Therapeutics’ Abstract (#3016) Selected for Oral Presentation as Part of a Poster Discussion Session at ASCO 2020.

US warning comes after wave of incidents in Europe, Australia, and New Zealand, where vandals damaged cellular antennas and made threats to telecom workers.

Sproutly Canada, Inc. (CSE:SPR) (OTCQB:SRUTF) (FSE:38G) (“Sproutly” or the “Company”) announces a business transformation plan that will shift the Com

Iovance Biotherapeutics, Inc. (IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced new interim data from Cohort 2 in the C-144-01 study of l

Gilead Sciences, Inc. (Nasdaq: GILD) and Kite, a Gilead Company, today announced the acceptance of nine abstracts, including three oral presentations